Supreme Life

, Ltd. operates primarily in diabetes management. The company has completed a total of 1 deal, with its most recent deal occurring on January 26, 2026., Ltd. specializes in diabetes management solutions, with a focus on innovative therapies that extend beyond traditional insulin and hypoglycemic treatments. Their core product offerings are designed to enhance patient care by integrating scientific education and patient case studies into their service model, thereby addressing the multifaceted needs of individuals living with diabetes. The company serves a diverse client base, including healthcare providers, clinics, and patients directly, primarily in urban centers across China and potentially in select international markets., Ltd. is built on direct-to-consumer and B2B models, engaging healthcare providers in partnerships to distribute their diabetes management products. Transactions typically involve subscription-based services for ongoing support and education, along with one-time purchases of proprietary devices or therapeutic products. This multi-faceted approach allows the company to establish long-term relationships with clients, ensuring a steady revenue stream. Specific pricing plans are aligned with the value provided, reflecting the advanced nature of the offerings that cater to both individual patients and healthcare institutions. The company aims to launch new products focused on enhancing diabetes management by mid-2026 and plans to expand into international markets, specifically targeting Southeast Asia and Europe by the end of 2027.

1. Series A

   Jan 26, 2026

   Amount

   Undisclosed

   Investors

   Locked